



## Clinical trial results:

**A national phase IIIb, multi-center, open label study for women and men with hormone-receptor positive, HER2-negative locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole RIBECCA RIBociclib for the treatment of advanced breast CAncer**

### Summary

EudraCT number	2016-002556-24
Trial protocol	DE
Global end of trial date	06 February 2020

### Results information

Result version number	v1
This version publication date	22 February 2021
First version publication date	22 February 2021

### Trial information

#### Trial identification

Sponsor protocol code	CLEE011XDE01
-----------------------	--------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03096847
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Novartis Pharmaceuticals
Sponsor organisation address	Novartis Campus, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharmaceuticals, 41 613241111, Novartis.email@Novartis.com
Scientific contact	Study Director , Novartis Pharmaceuticals, 41 613241111, Novartis.email@Novartis.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	06 February 2020
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	06 February 2020
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this study was the assessment of the clinical benefit rate (CBR) after 24 weeks for the total population and for cohorts A and B separately:

-To assess the CBR after 24 weeks for ribociclib (LEE011) in combination with letrozole among postmenopausal women and men with hormone receptor positive, HER2- negative, advanced breast cancer who received no prior treatment for advanced disease. (70% group) (Cohort A)

-To assess the CBR after 24 weeks for ribociclib (LEE011) in combination with letrozole and goserelin among pre-, and perimenopausal women who received no prior treatment for advanced disease as well as pre-, peri- and postmenopausal women and men with hormone receptor positive, HER2- negative, advanced breast cancer who received no more than 1 prior chemotherapy and 2 prior lines of endocrine therapy for advanced disease (30% group) (Cohort B)

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	24 October 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 502
Worldwide total number of subjects	502
EEA total number of subjects	502

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	256
From 65 to 84 years	240
85 years and over	6

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

584 patients were screened and defined as Cohort A, 191 patients defined Cohort B. Cohort B was divided into Cohort B1 comprising 34 pre- or perimenopausal women without prior treatment (treatment naïve) and Cohort B2 comprising 157 women or men with prior treatment (pretreated).

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	ribociclib + letrozole cohort A

Arm description:

postmenopausal women, or men; naïve. All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.

Arm type	Experimental
Investigational medicinal product name	ribociclib and letrozole
Investigational medicinal product code	ribociclib (LEE011)
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Ribociclib - 600 mg (3 x 200mg) - Once daily - Days 1-21 of each 28-day cycle; Letrozole - 2.5 mg - Once daily

<b>Arm title</b>	ribociclib + letrozole cohort B1
------------------	----------------------------------

Arm description:

premenopausal women or perimenopausal women; naïve All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily. Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly

Arm type	Experimental
Investigational medicinal product name	Ribociclib and Letrozole and Goserelin (for premenopausal patients)
Investigational medicinal product code	ribociclib (LEE011)
Other name	
Pharmaceutical forms	Tablet, Implant
Routes of administration	Oral use, Subcutaneous use

Dosage and administration details:

Ribociclib - 600 mg (3 x 200mg) - Once daily - Days 1-21 of each 28-day cycle; Letrozole - 2.5 mg - Once daily; Goserelin (for premenopausal patients) - 3.6 mg - Day 1 of each cycle

<b>Arm title</b>	ribociclib + letrozole cohort B2
------------------	----------------------------------

Arm description:

premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated. All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily. Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Ribociclib and Letrozole and Goserelin (for premenopausal patients)
Investigational medicinal product code	ribociclib (LEE011)
Other name	
Pharmaceutical forms	Tablet, Implant
Routes of administration	Oral use, Subcutaneous use

Dosage and administration details:

Ribociclib - 600 mg (3 x 200mg) - Once daily - Days 1-21 of each 28-day cycle; Letrozole - 2.5 mg - Once daily; Goserelin (for premenopausal patients) - 3.6 mg - Day 1 of each cycle

<b>Number of subjects in period 1</b>	ribociclib + letrozole cohort A	ribociclib + letrozole cohort B1	ribociclib + letrozole cohort B2
Started	319	26	157
Completed	100	6	19
Not completed	219	20	138
Adverse event, serious fatal	6	-	2
Physician decision	12	2	8
Consent withdrawn by subject	24	1	12
Adverse event, non-fatal	72	6	28
Non-compliance with study medication	1	-	-
Lost to follow-up	1	-	1
Progressive disease	97	10	78
New therapy for study indication	1	-	1
not specified	2	1	2
Protocol deviation	3	-	6

## Baseline characteristics

### Reporting groups

Reporting group title	ribociclib + letrozole cohort A
Reporting group description: postmenopausal women, or men; naïve. All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.	
Reporting group title	ribociclib + letrozole cohort B1
Reporting group description: premenopausal women or perimenopausal women; naïve All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily. Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly	
Reporting group title	ribociclib + letrozole cohort B2
Reporting group description: premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated. All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily. Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly	

Reporting group values	ribociclib + letrozole cohort A	ribociclib + letrozole cohort B1	ribociclib + letrozole cohort B2
Number of subjects	319	26	157
Age Categorical Units: Participants			
<=18 years	0	0	0
Between 18 and 65 years	143	26	87
>=65 years	176	0	70
Age Continuous Units: Years			
arithmetic mean	65.7	46.5	62.8
standard deviation	± 10.1	± 4.9	± 12.8
Sex: Female, Male Units: Participants			
Female	315	26	156
Male	4	0	1
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	1	1
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	1	0
White	312	24	151
More than one race	1	0	3
Unknown or Not Reported	6	0	2

Reporting group values	Total		
Number of subjects	502		
Age Categorical Units: Participants			
<=18 years	0		
Between 18 and 65 years	256		

>=65 years	246		
------------	-----	--	--

Age Continuous Units: Years arithmetic mean standard deviation	-		
Sex: Female, Male Units: Participants			
Female	497		
Male	5		
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0		
Asian	2		
Native Hawaiian or Other Pacific Islander	0		
Black or African American	1		
White	487		
More than one race	4		
Unknown or Not Reported	8		

## End points

### End points reporting groups

Reporting group title	ribociclib + letrozole cohort A
Reporting group description: postmenopausal women, or men; naïve. All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.	
Reporting group title	ribociclib + letrozole cohort B1
Reporting group description: premenopausal women or perimenopausal women; naïve All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily. Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly	
Reporting group title	ribociclib + letrozole cohort B2
Reporting group description: premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated. All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily. Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly	
Subject analysis set title	ribociclib + letrozole cohort A
Subject analysis set type	Safety analysis
Subject analysis set description: postmenopausal women, or men; naïve.	
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.	
Subject analysis set title	ribociclib + letrozole cohort B
Subject analysis set type	Safety analysis
Subject analysis set description: premenopausal women or perimenopausal women or postmenopausal women, or men; naïve + pre-treated	
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o.daily.	
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly	
Subject analysis set title	ribociclib + letrozole cohort B1
Subject analysis set type	Safety analysis
Subject analysis set description: premenopausal women or perimenopausal women; naïve	
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.	
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly	
Subject analysis set title	ribociclib + letrozole cohort B2
Subject analysis set type	Safety analysis
Subject analysis set description: premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated.	
All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.	
Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly	
Subject analysis set title	Total
Subject analysis set type	Safety analysis
Subject analysis set description: Total	



**Primary: Clinical Benefit Rate (CBR) in women and men with hormone receptor positiv, HER-2 negative breast cancer treated with ribociclib and letrozole**

End point title	Clinical Benefit Rate (CBR) in women and men with hormone receptor positiv, HER-2 negative breast cancer treated with ribociclib and letrozole <sup>[1]</sup>
-----------------	---

End point description:

Clinical Benefit Rate (CBR) after 24 weeks of treatment as defined by RECIST 1.1 as percentage of patients with Complete Response (CR), Partial response (PR) or Stable disease (SD) lasting 24 weeks or longer as well as patients with NCRNPD >24 for patients with non-measurable disease

End point type	Primary
----------------	---------

End point timeframe:

At 24 weeks after last patient enrolled in trial

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Summary statistics is available although statistical analysis is not.

End point values	ribociclib + letrozole cohort A	ribociclib + letrozole cohort B	Total	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	307	180	487	
Units: Percentage of Participants				
number (confidence interval 95%)				
CBR by week 24)(Confirmed BOR)	63.2 (57.5 to 68.6)	56.7 (49.1 to 64.0)	60.8 (56.3 to 65.1)	
CBR by week 24(non-confirmed BOR)	71.7 (66.3 to 76.6)	65.0 (57.6 to 71.9)	69.2 (64.9 to 73.3)	

**Statistical analyses**

No statistical analyses for this end point

**Secondary: CBR**

End point title	CBR
-----------------	-----

End point description:

To assess the CBR after 24 weeks among pre- and perimenopausal women without prior therapy for advanced disease (Cohort B1); To assess the CBR after 24 weeks for ribociclib among pre-, peri- and postmenopausal women and men who were pretreated for advanced disease (Cohort B2)

End point type	Secondary
----------------	-----------

End point timeframe:

At 24 weeks

End point values	ribociclib + letrozole cohort A	ribociclib + letrozole cohort B1	ribociclib + letrozole cohort B2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0 <sup>[2]</sup>	26	154	
Units: Percentage of Participants				
number (confidence interval 95%)				

CBR by week 24 – confirmed assessment	( to )	57.7 (36.9 to 76.6)	56.5 (48.3 to 64.5)	
CBR by week 24 – unconfirmed assessment	( to )	69.2 (48.2 to 85.7)	64.3 (56.2 to 71.8)	

Notes:

[2] - measure not applicable for this arm.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Progression free survival (PFS) for different populations - Kaplan-Meier estimates (% , 95% CI)

End point title	Progression free survival (PFS) for different populations - Kaplan-Meier estimates (% , 95% CI)
End point description:	PFS based on radiologic assessment by investigator using RECIST 1.1 criteria
End point type	Secondary
End point timeframe:	At week 24 , week 48 and week 72

End point values	ribociclib + letrozole cohort A	ribociclib + letrozole cohort B1	ribociclib + letrozole cohort B2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	307	26	154	
Units: Percentage of Participants				
number (confidence interval 95%)				
Kaplan-Meier estimates (% , 95% CI) - Week 24	73.1 (67.3 to 77.9)	67.0 (44.7 to 82.0)	63.8 (55.2 to 71.3)	
Kaplan-Meier estimates (% , 95% CI) - Week 48	61.9 (55.7 to 67.5)	58.7 (36.8 to 75.2)	47.5 (38.7 to 55.7)	
Kaplan-Meier estimates (% , 95% CI) - week 72	54.5 (48.1 to 60.5)	49.6 (28.6 to 67.6)	39.3 (30.8 to 47.6)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Progression free survival (PFS) for different populations - Median time to progression or death with 95% CI [months]

End point title	Progression free survival (PFS) for different populations - Median time to progression or death with 95% CI [months]
End point description:	PFS based on radiologic assessment by investigator using RECIST 1.1 criteria
End point type	Secondary
End point timeframe:	Up to approximately month 25

End point values	ribociclib + letrozole cohort A	ribociclib + letrozole cohort B1	ribociclib + letrozole cohort B2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	307	26	154	
Units: Months				
median (confidence interval 95%)	21.8 (13.9 to 25.3)	16.5 (3.2 to 999)	8.8 (8.1 to 16.3)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Overall Survival (OS) - Kaplan-Meier estimates (% , 95% CI)

End point title	Overall Survival (OS) - Kaplan-Meier estimates (% , 95% CI)
End point description:	
Overall survival (OS) defined as the time from date of start of treatment to date of death due to any cause.	
End point type	Secondary
End point timeframe:	
At Week 24, Week 48 and Week 72	

End point values	ribociclib + letrozole cohort A	ribociclib + letrozole cohort B1	ribociclib + letrozole cohort B2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	307	26	154	
Units: Percentage of Participants				
number (confidence interval 95%)				
Kaplan-Meier estimates (% , 95% CI) - Week 24	98.6 (96.4 to 99.5)	100.0 (100.0 to 100.0)	93.9 (88.5 to 96.8)	
Kaplan-Meier estimates (% , 95% CI) - Week 48	93.3 (89.7 to 95.7)	87.5 (66.1 to 95.8)	86.1 (79.2 to 90.8)	
Kaplan-Meier estimates (% , 95% CI) - Week 72	89.7 (85.5 to 92.7)	87.5 (66.1 to 95.8)	81.0 (73.5 to 86.6)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Overall Survival (OS) - Median time to progression or death with 95% CI [months]

End point title	Overall Survival (OS) - Median time to progression or death
-----------------	---

End point description:

Overall survival (OS) defined as the time from date of start of treatment to date of death due to any cause.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 38 months

End point values	ribociclib + letrozole cohort A	ribociclib + letrozole cohort B1	ribociclib + letrozole cohort B2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	307	26	154	
Units: Months				
median (confidence interval 95%)	999 (999 to 999)	999 (30.9 to 999)	999 (31.0 to 999)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Survival (OS) - number of deaths

End point title	Overall Survival (OS) - number of deaths
-----------------	--

End point description:

Overall survival (OS) defined as the time from date of start of treatment to date of death due to any cause.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 38 months

End point values	ribociclib + letrozole cohort A	ribociclib + letrozole cohort B1	ribociclib + letrozole cohort B2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	307	26	154	
Units: Participants				
No. of censored (no death), n	240	17	94	
No. of events (deaths due to any cause), n	67	9	60	

## Statistical analyses

No statistical analyses for this end point

**Secondary: Overall response rate (ORR) - Kaplan-Meier estimates (% , 95% CI)**

End point title	Overall response rate (ORR) - Kaplan-Meier estimates (% , 95% CI)
End point description:	
Overall response rate (ORR) defined as complete response or partial response as defined by RECIST 1.1	
End point type	Secondary
End point timeframe:	
At week 24	

End point values	ribociclib + letrozole cohort A	ribociclib + letrozole cohort B1	ribociclib + letrozole cohort B2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	307	26	154	
Units: Percentage of Participants				
number (confidence interval 95%)				
ORR by week 24 - (BOR of CR or PR) (confirmed)	22.8 (18.2 to 27.9)	23.1 (9.0 to 43.6)	11.7 (7.1 to 17.8)	
ORR by week 24 - (BOR of CR or PR) (unconfirmed)	24.8 (20.0 to 30.0)	30.8 (14.3 to 51.8)	16.2 (10.8 to 23.0)	

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Patient reported Quality of Life (QoL) via EORTC QLQ-C30**

End point title	Patient reported Quality of Life (QoL) via EORTC QLQ-C30
End point description:	
The QLQ-C30 is the core questionnaire of the EORTC QLQ, which has been developed for the assessment of the health-related QOL of cancer patients participating in international clinical trials (Aaronson et al. 1993).	
Using a linear transformation to standardize the raw scores, all scores finally range from 0 to 100, where a higher score represents a higher response level, e.g., a higher ("better") level of functioning, but a higher ("worse") level of symptoms (Fayers et al. 2001). There is no aggregated total score, i.e., all scale scores were analyzed separately.	
End point type	Secondary
End point timeframe:	
Change from Baseline to Week 24	

End point values	ribociclib + letrozole cohort A	ribociclib + letrozole cohort B		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	307	154		
Units: Scores on a scale				
arithmetic mean (standard deviation)				

Global health status-Change from b/l to Wk 24	8.8 (± 23.7)	5.0 (± 26.2)		
Physical Functioning-Change from b/l to Wk 24	-3.1 (± 19.9)	-2.2 (± 17.7)		
Role Functioning-Change from b/l to Wk 24	-6.6 (± 31.9)	-1.3 (± 34.7)		
Emotional Functioning-Change from b/l to Wk 24	-9.6 (± 24.2)	-3.6 (± 21.8)		
Cognitive Functioning-Change from b/l to Wk 24	2.7 (± 23.7)	1.1 (± 21.6)		
Social Functioning-Change from b/l to Wk 24	-6.9 (± 27.9)	-5.3 (± 31.3)		
Fatigue - Change from baseline to Wk 24	6.3 (± 25.9)	3.9 (± 27.1)		
Nausea / Vomiting-Change from b/l to Wk 24	0.1 (± 16.7)	-4.9 (± 19.1)		
Pain-Change from baseline to Wk 24	13.2 (± 31.9)	9.0 (± 27.6)		
Dyspnoea-Change from baseline to Wk 24	3.8 (± 32.4)	-5.3 (± 30.5)		
Insomnia-Change from baseline to Wk 24	4.2 (± 33.2)	4.9 (± 32.7)		
Appetite loss-Change from baseline to Wk 24	11.2 (± 33.7)	1.4 (± 30.9)		
Constipation-Change from baseline to Wk 24	-2.7 (± 26.6)	-3.6 (± 27.9)		
Diarrhea-Change from baseline to Wk 24	2.6 (± 24.6)	2.3 (± 27.2)		
Financial Problems-Change from b/l to Wk 24	0.2 (± 27.7)	-1.4 (± 25.1)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Patient reported Quality of Life (QoL) via EORTC BR-23 - change from baseline at Week 24 (Cycle 7)

End point title	Patient reported Quality of Life (QoL) via EORTC BR-23 - change from baseline at Week 24 (Cycle 7)
-----------------	--

End point description:

To evaluate health related quality of life (QoL) via EORTC BR-23. The scoring approach for the QLQ-BR23 is identical in principle to that for the function and symptom scales / single items of the QLQ-C30, i.e., all scores finally range from 0 to 100, where a higher score represents a higher response level, e.g., a higher ("better") level of functioning, but a higher ("worse") level of symptoms (Fayers et al. 2001).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 24 (Cycle 7)

End point values	ribociclib + letrozole cohort A	ribociclib + letrozole cohort B		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	307	154		
Units: Scores on a scale				
arithmetic mean (standard deviation)				
BODY IMAGE - change from b/l at cycle 7	-1.5 (± 18.2)	0.4 (± 22.7)		
SEXUAL FUNCTIONING - change from b/l at cycle 7	-1.1 (± 17.7)	0.8 (± 18.0)		
SEXUAL ENJOYMENT - change from b/l at cycle 7	-1.9 (± 31.3)	7.4 (± 26.9)		
FUTURE PERSPECTIVE - change from b/l at cycle 7	-20 (± 33.4)	-12 (± 26.2)		
SYSTEMATIC THERAPY - change from b/l at cycle 7	-9.4 (± 16.6)	-6.0 (± 14.9)		
BREAST SYMPTOMS - change from b/l at cycle 7	3.3 (± 15.7)	0.9 (± 17.5)		
ARM SYMPTOMS - change from b/l at cycle 7	4.1 (± 21.1)	-2.1 (± 18.1)		
HAIR LOSS - change from baseline at cycle 7	-22 (± 43.4)	-14 (± 33.9)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: To evaluate the safety and tolerability of ribociclib in combination with letrozole (and goserelin in premenopausal patients) - via collection of Treatment Emergent Adverse Events (TEAE)

End point title	To evaluate the safety and tolerability of ribociclib in combination with letrozole (and goserelin in premenopausal patients) - via collection of Treatment Emergent Adverse Events (TEAE)
End point description:	AEs were separated into TEAEs (defined as AEs occurring/worsening from first study drug treatment until 30 days after the last study drug treatment) and AEs in the pre-/post-treatment period.
End point type	Secondary
End point timeframe:	Up to Week 72

End point values	ribociclib + letrozole cohort A	ribociclib + letrozole cohort B1	ribociclib + letrozole cohort B2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	319	26	157	
Units: Number of Participants				
Total AEs	318	25	157	
Serious AE	97	5	45	
Non-serious AE	317	25	157	

AE with suspected relationship to ribociclib	302	25	144	
AE leading to discontinuation of ribociclib	76	7	38	
AE with fatal outcome	6	0	6	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to 10% deterioration in the European Organisation for Research and Treatment of Cancer (EORTC) global health status

End point title	Time to 10% deterioration in the European Organisation for Research and Treatment of Cancer (EORTC) global health status
End point description:	Time to 10% deterioration in the European Organisation for Research and Treatment of Cancer (EORTC) global health status
End point type	Secondary
End point timeframe:	up to approximately 10 months

End point values	ribociclib + letrozole cohort A	ribociclib + letrozole cohort B1	ribociclib + letrozole cohort B2	Total
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	307	26	154	487
Units: months				
median (confidence interval 95%)	3.3 (2.8 to 4.6)	3.7 (1.8 to 10.1)	2.8 (1.8 to 4.6)	3.0 (2.8 to 4.6)

## Statistical analyses

No statistical analyses for this end point

## Post-hoc: All Collected Deaths

End point title	All Collected Deaths
End point description:	On treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration of 1150 days (approx 3.15 years). (Treatment duration ranged from 2 days to 1120 days). Deaths post treatment survival follow up were collected after the on- treatment period, up to approx. 3.15 years. Patients who didn't die during the on-treatment period and had not stopped study participation at the time of data cut-off (end of study) were censored.
End point type	Post-hoc
End point timeframe:	on-treatment deaths: up to approx 3.15 years; all deaths: approx 3.15 years



<b>End point values</b>	ribociclib + letrozole cohort A	ribociclib + letrozole cohort B	Total	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	319 <sup>[3]</sup>	183 <sup>[4]</sup>	502 <sup>[5]</sup>	
Units: Participants				
on-treatment deaths	6	6	12	
Total deaths	67	69	136	

Notes:

[3] - n = 319 for on-treatment deaths;  
n = 307 for total deaths

[4] - n = 183 for on-treatment deaths;  
n = 180 for total deaths

[5] - n = 502 for on-treatment deaths;  
n = 487 for total deaths

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days, up to a maximum duration of 1150 days (approx. 3.15 years). (Treatment duration ranged from 2 days to 1120 days.)

Adverse event reporting additional description:

Consistent with EudraCT disclosure specifications, Novartis has reported under the Serious adverse events field "number of deaths resulting from adverse events" all those deaths, resulting from serious adverse events that are deemed to be causally related to treatment by the investigator.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.1
--------------------	------

### Reporting groups

Reporting group title	ribociclib + letrozole cohort A
-----------------------	---------------------------------

Reporting group description:

postmenopausal women, or men; naïve.

All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.

Reporting group title	ribociclib + letrozole cohort B
-----------------------	---------------------------------

Reporting group description:

premenopausal women  
or perimenopausal women or postmenopausal  
women, or men; naïve + pre-treated

All patients received ribociclib 600mg p.o. daily  
+ Letrozole 2.5 mg p.o.daily.

Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly

Reporting group title	ribociclib + letrozole cohort B1
-----------------------	----------------------------------

Reporting group description:

premenopausal women or perimenopausal women; naïve

All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.

Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly

Reporting group title	ribociclib + letrozole cohort B2
-----------------------	----------------------------------

Reporting group description:

premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated.

All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.

Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly

Reporting group title	Total
-----------------------	-------

Reporting group description:

Total

Serious adverse events	ribociclib + letrozole cohort A	ribociclib + letrozole cohort B	ribociclib + letrozole cohort B1
Total subjects affected by serious adverse events			
subjects affected / exposed	97 / 319 (30.41%)	50 / 183 (27.32%)	5 / 26 (19.23%)

number of deaths (all causes)	6	6	0
number of deaths resulting from adverse events	1	1	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
BRONCHIAL CARCINOMA			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CANCER PAIN			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COLON CANCER			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MALIGNANT PLEURAL EFFUSION			
subjects affected / exposed	2 / 319 (0.63%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
METASTASES TO BONE			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
METASTASES TO SPINE			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RENAL CELL CARCINOMA			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SQUAMOUS CELL CARCINOMA OF THE TONGUE			

subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TUMOUR PAIN			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
CIRCULATORY COLLAPSE			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERTENSION			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERTENSIVE CRISIS			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPOTENSION			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
CHEST PAIN			
subjects affected / exposed	1 / 319 (0.31%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COMPLICATION OF DEVICE INSERTION			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

DEATH			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
FATIGUE			
subjects affected / exposed	0 / 319 (0.00%)	2 / 183 (1.09%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GENERAL PHYSICAL HEALTH DETERIORATION			
subjects affected / exposed	2 / 319 (0.63%)	5 / 183 (2.73%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 3	2 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
IMPAIRED HEALING			
subjects affected / exposed	1 / 319 (0.31%)	2 / 183 (1.09%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OEDEMA PERIPHERAL			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PAIN			
subjects affected / exposed	1 / 319 (0.31%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PYREXIA			
subjects affected / exposed	6 / 319 (1.88%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	3 / 6	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
PELVIC PAIN			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Respiratory, thoracic and mediastinal disorders			
ASTHMA			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DYSPNOEA			
subjects affected / exposed	9 / 319 (2.82%)	3 / 183 (1.64%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	3 / 10	0 / 3	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 1	0 / 0
DYSPNOEA EXERTIONAL			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERVENTILATION			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PLEURAL EFFUSION			
subjects affected / exposed	3 / 319 (0.94%)	3 / 183 (1.64%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
PNEUMONITIS			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMOTHORAX			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PULMONARY EMBOLISM			
subjects affected / exposed	7 / 319 (2.19%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 7	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0

PULMONARY FIBROSIS			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RESPIRATORY FAILURE			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Psychiatric disorders			
DEPRESSION			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PANIC ATTACK			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SOMATIC SYMPTOM DISORDER			
subjects affected / exposed	2 / 319 (0.63%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
DEVICE LOOSENING			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
ALANINE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	5 / 319 (1.57%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	5 / 5	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ASPARTATE AMINOTRANSFERASE INCREASED			

subjects affected / exposed	3 / 319 (0.94%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	3 / 3	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>BLOOD BILIRUBIN INCREASED</b>			
subjects affected / exposed	1 / 319 (0.31%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>C-REACTIVE PROTEIN INCREASED</b>			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>HAEMOGLOBIN DECREASED</b>			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>NEUTROPHIL COUNT DECREASED</b>			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>WHITE BLOOD CELL COUNT DECREASED</b>			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Injury, poisoning and procedural complications</b>			
<b>ACCIDENT</b>			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>ANKLE FRACTURE</b>			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>CERVICAL VERTEBRAL FRACTURE</b>			



subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FALL			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FEMORAL NECK FRACTURE			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FEMUR FRACTURE			
subjects affected / exposed	3 / 319 (0.94%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HIP FRACTURE			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HUMERUS FRACTURE			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INCISIONAL HERNIA			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
JAW FRACTURE			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
POST PROCEDURAL HAEMORRHAGE			

subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
POST-TRAUMATIC PAIN			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
POSTOPERATIVE ADHESION			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PROCEDURAL COMPLICATION			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RADIUS FRACTURE			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RIB FRACTURE			
subjects affected / exposed	3 / 319 (0.94%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TIBIA FRACTURE			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
UPPER LIMB FRACTURE			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
ATRIAL FIBRILLATION			

subjects affected / exposed	2 / 319 (0.63%)	2 / 183 (1.09%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BRADYARRHYTHMIA			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC ARREST			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC FAILURE			
subjects affected / exposed	1 / 319 (0.31%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
MYOCARDIAL INFARCTION			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SUPRAVENTRICULAR TACHYCARDIA			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
CEREBRAL ISCHAEMIA			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CEREBROVASCULAR ACCIDENT			
subjects affected / exposed	2 / 319 (0.63%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DIZZINESS			

subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HEADACHE			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MONOPLÉGIA			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NEUROPATHY PERIPHERAL			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PARAESTHESIA			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PERIPHERAL NERVE LESION			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SYNCOPE			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	4 / 319 (1.25%)	4 / 183 (2.19%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	10 / 11	10 / 12	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DISSEMINATED INTRAVASCULAR COAGULATION			

subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>FEBRILE NEUTROPENIA</b>			
subjects affected / exposed	0 / 319 (0.00%)	3 / 183 (1.64%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	3 / 3	1 / 1
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
<b>HYPERFIBRINOLYSIS</b>			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>LEUKOPENIA</b>			
subjects affected / exposed	2 / 319 (0.63%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>NEUTROPENIA</b>			
subjects affected / exposed	2 / 319 (0.63%)	2 / 183 (1.09%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 2	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>PANCYTOPENIA</b>			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>THROMBOCYTOPENIA</b>			
subjects affected / exposed	3 / 319 (0.94%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	4 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal disorders</b>			
<b>ABDOMINAL PAIN</b>			
subjects affected / exposed	1 / 319 (0.31%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>ABDOMINAL PAIN LOWER</b>			

subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ANAL HAEMORRHAGE			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CONSTIPATION			
subjects affected / exposed	2 / 319 (0.63%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DIARRHOEA			
subjects affected / exposed	3 / 319 (0.94%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTRITIS			
subjects affected / exposed	3 / 319 (0.94%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTROOESOPHAGEAL REFLUX DISEASE			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ILEUS			
subjects affected / exposed	1 / 319 (0.31%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
INTESTINAL STRANGULATION			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NAUSEA			

subjects affected / exposed	7 / 319 (2.19%)	2 / 183 (1.09%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	2 / 8	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
VOMITING			
subjects affected / exposed	3 / 319 (0.94%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
BILE DUCT STENOSIS			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BILIARY COLIC			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHOLECYSTITIS			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHOLECYSTITIS ACUTE			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHOLELITHIASIS			
subjects affected / exposed	2 / 319 (0.63%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DRUG-INDUCED LIVER INJURY			
subjects affected / exposed	5 / 319 (1.57%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	6 / 6	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HEPATIC CIRRHOSIS			

subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HEPATOTOXICITY			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
JAUNDICE			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
SKIN ULCER			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
ACUTE KIDNEY INJURY			
subjects affected / exposed	5 / 319 (1.57%)	1 / 183 (0.55%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 5	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
HAEMATURIA			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
KIDNEY CONGESTION			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RENAL DISORDER			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RENAL FAILURE			



subjects affected / exposed	1 / 319 (0.31%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RENAL IMPAIRMENT			
subjects affected / exposed	1 / 319 (0.31%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URETERIC STENOSIS			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URETEROLITHIASIS			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY INCONTINENCE			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY RETENTION			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY TRACT OBSTRUCTION			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
HYPERTHYROIDISM			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			

ARTHRALGIA			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BACK PAIN			
subjects affected / exposed	2 / 319 (0.63%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BONE LESION			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BONE PAIN			
subjects affected / exposed	2 / 319 (0.63%)	2 / 183 (1.09%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FLANK PAIN			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LUMBAR SPINAL STENOSIS			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MOBILITY DECREASED			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MUSCULOSKELETAL CHEST PAIN			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MUSCULOSKELETAL PAIN			

subjects affected / exposed	1 / 319 (0.31%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OSTEITIS			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OSTEOARTHRITIS			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OSTEONECROSIS OF JAW			
subjects affected / exposed	2 / 319 (0.63%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PAIN IN EXTREMITY			
subjects affected / exposed	2 / 319 (0.63%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SPINAL PAIN			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
ABDOMINAL ABSCESS			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ABSCESS JAW			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
APPENDICITIS			

subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ATYPICAL PNEUMONIA			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BRONCHITIS			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHOLECYSTITIS INFECTIVE			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CYSTITIS			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CYSTITIS ESCHERICHIA			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DEVICE RELATED INFECTION			
subjects affected / exposed	0 / 319 (0.00%)	2 / 183 (1.09%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
DIVERTICULITIS			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
EMPHYSEMATOUS CHOLECYSTITIS			

subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ERYSIPELAS			
subjects affected / exposed	3 / 319 (0.94%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ESCHERICHIA INFECTION			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FEBRILE INFECTION			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTROENTERITIS			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTROINTESTINAL INFECTION			
subjects affected / exposed	1 / 319 (0.31%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HELICOBACTER GASTRITIS			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INFECTIOUS PLEURAL EFFUSION			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INFLUENZA			

subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MASTITIS			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA			
subjects affected / exposed	8 / 319 (2.51%)	2 / 183 (1.09%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	2 / 8	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 2	1 / 1	0 / 0
PROTEUS INFECTION			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PYELONEPHRITIS			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RESPIRATORY SYNCYTIAL VIRUS INFECTION			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEPSIS			
subjects affected / exposed	1 / 319 (0.31%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY TRACT INFECTION			

subjects affected / exposed	3 / 319 (0.94%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	2 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
UROSEPSIS			
subjects affected / exposed	2 / 319 (0.63%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
DECREASED APPETITE			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DEHYDRATION			
subjects affected / exposed	1 / 319 (0.31%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERCALCAEMIA			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERKALAEMIA			
subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPONATRAEMIA			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPOPHAGIA			
subjects affected / exposed	1 / 319 (0.31%)	0 / 183 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TUMOUR LYSIS SYNDROME			

subjects affected / exposed	0 / 319 (0.00%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	ribociclib + letrozole cohort B2	Total	
Total subjects affected by serious adverse events			
subjects affected / exposed	45 / 157 (28.66%)	147 / 502 (29.28%)	
number of deaths (all causes)	6	12	
number of deaths resulting from adverse events	1	2	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
BRONCHIAL CARCINOMA			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CANCER PAIN			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
COLON CANCER			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MALIGNANT PLEURAL EFFUSION			
subjects affected / exposed	0 / 157 (0.00%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
METASTASES TO BONE			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
METASTASES TO SPINE			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	



RENAL CELL CARCINOMA			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SQUAMOUS CELL CARCINOMA OF THE TONGUE			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
TUMOUR PAIN			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
CIRCULATORY COLLAPSE			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERTENSION			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERTENSIVE CRISIS			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPOTENSION			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
CHEST PAIN			

subjects affected / exposed	1 / 157 (0.64%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
COMPLICATION OF DEVICE INSERTION			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEATH			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
FATIGUE			
subjects affected / exposed	2 / 157 (1.27%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
GENERAL PHYSICAL HEALTH DETERIORATION			
subjects affected / exposed	5 / 157 (3.18%)	7 / 502 (1.39%)	
occurrences causally related to treatment / all	2 / 5	3 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
IMPAIRED HEALING			
subjects affected / exposed	2 / 157 (1.27%)	3 / 502 (0.60%)	
occurrences causally related to treatment / all	0 / 2	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
OEDEMA PERIPHERAL			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PAIN			
subjects affected / exposed	1 / 157 (0.64%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
PYREXIA			

subjects affected / exposed	1 / 157 (0.64%)	7 / 502 (1.39%)	
occurrences causally related to treatment / all	0 / 1	3 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
PELVIC PAIN			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
ASTHMA			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DYSпноEA			
subjects affected / exposed	3 / 157 (1.91%)	12 / 502 (2.39%)	
occurrences causally related to treatment / all	0 / 3	3 / 13	
deaths causally related to treatment / all	0 / 1	1 / 2	
DYSпноEA EXERTIONAL			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERVENTILATION			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PLEURAL EFFUSION			
subjects affected / exposed	3 / 157 (1.91%)	6 / 502 (1.20%)	
occurrences causally related to treatment / all	0 / 4	0 / 7	
deaths causally related to treatment / all	0 / 1	0 / 1	
PNEUMONITIS			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

PNEUMOTHORAX	subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
	occurrences causally related to treatment / all	0 / 0	0 / 1	
	deaths causally related to treatment / all	0 / 0	0 / 0	
PULMONARY EMBOLISM	subjects affected / exposed	1 / 157 (0.64%)	8 / 502 (1.59%)	
	occurrences causally related to treatment / all	0 / 1	1 / 8	
	deaths causally related to treatment / all	0 / 1	0 / 2	
PULMONARY FIBROSIS	subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
	occurrences causally related to treatment / all	0 / 0	0 / 1	
	deaths causally related to treatment / all	0 / 0	0 / 0	
RESPIRATORY FAILURE	subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
	occurrences causally related to treatment / all	0 / 0	0 / 1	
	deaths causally related to treatment / all	0 / 0	0 / 1	
Psychiatric disorders				
DEPRESSION	subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
	occurrences causally related to treatment / all	0 / 1	0 / 1	
	deaths causally related to treatment / all	0 / 0	0 / 0	
PANIC ATTACK	subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
	occurrences causally related to treatment / all	0 / 1	0 / 1	
	deaths causally related to treatment / all	0 / 0	0 / 0	
SOMATIC SYMPTOM DISORDER	subjects affected / exposed	0 / 157 (0.00%)	2 / 502 (0.40%)	
	occurrences causally related to treatment / all	0 / 0	0 / 2	
	deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues				
DEVICE LOOSENING	subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
	occurrences causally related to treatment / all	0 / 1	0 / 1	
	deaths causally related to treatment / all	0 / 0	0 / 0	

Investigations			
ALANINE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	1 / 157 (0.64%)	6 / 502 (1.20%)	
occurrences causally related to treatment / all	1 / 1	6 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
ASPARTATE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	1 / 157 (0.64%)	4 / 502 (0.80%)	
occurrences causally related to treatment / all	1 / 1	4 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
BLOOD BILIRUBIN INCREASED			
subjects affected / exposed	1 / 157 (0.64%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
C-REACTIVE PROTEIN INCREASED			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HAEMOGLOBIN DECREASED			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
NEUTROPHIL COUNT DECREASED			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
WHITE BLOOD CELL COUNT DECREASED			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
ACCIDENT			

subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ANKLE FRACTURE			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CERVICAL VERTEBRAL FRACTURE			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
FALL			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
FEMORAL NECK FRACTURE			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
FEMUR FRACTURE			
subjects affected / exposed	0 / 157 (0.00%)	3 / 502 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
HIP FRACTURE			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HUMERUS FRACTURE			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
INCISIONAL HERNIA			

subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
JAW FRACTURE			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
POST PROCEDURAL HAEMORRHAGE			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
POST-TRAUMATIC PAIN			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
POSTOPERATIVE ADHESION			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PROCEDURAL COMPLICATION			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RADIUS FRACTURE			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RIB FRACTURE			
subjects affected / exposed	0 / 157 (0.00%)	3 / 502 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
TIBIA FRACTURE			

subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
UPPER LIMB FRACTURE			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
ATRIAL FIBRILLATION			
subjects affected / exposed	2 / 157 (1.27%)	4 / 502 (0.80%)	
occurrences causally related to treatment / all	0 / 2	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
BRADYARRHYTHMIA			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIAC ARREST			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIAC FAILURE			
subjects affected / exposed	1 / 157 (0.64%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
MYOCARDIAL INFARCTION			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUPRAVENTRICULAR TACHYCARDIA			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			



CEREBRAL ISCHAEMIA			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CEREBROVASCULAR ACCIDENT			
subjects affected / exposed	0 / 157 (0.00%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIZZINESS			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HEADACHE			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MONOPLÉGIA			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
NEUROPATHY PERIPHERAL			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PARAESTHESIA			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERIPHERAL NERVE LESION			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SYNCOPE			

subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Blood and lymphatic system disorders</b>			
<b>ANAEMIA</b>			
subjects affected / exposed	4 / 157 (2.55%)	8 / 502 (1.59%)	
occurrences causally related to treatment / all	10 / 12	20 / 23	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>DISSEMINATED INTRAVASCULAR COAGULATION</b>			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>FEBRILE NEUTROPENIA</b>			
subjects affected / exposed	2 / 157 (1.27%)	3 / 502 (0.60%)	
occurrences causally related to treatment / all	2 / 2	3 / 3	
deaths causally related to treatment / all	1 / 1	1 / 1	
<b>HYPERFIBRINOLYSIS</b>			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>LEUKOPENIA</b>			
subjects affected / exposed	0 / 157 (0.00%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>NEUTROPENIA</b>			
subjects affected / exposed	2 / 157 (1.27%)	4 / 502 (0.80%)	
occurrences causally related to treatment / all	1 / 2	2 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>PANCYTOPENIA</b>			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>THROMBOCYTOPENIA</b>			

subjects affected / exposed	0 / 157 (0.00%)	3 / 502 (0.60%)	
occurrences causally related to treatment / all	0 / 0	4 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastrointestinal disorders</b>			
<b>ABDOMINAL PAIN</b>			
subjects affected / exposed	1 / 157 (0.64%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 3	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>ABDOMINAL PAIN LOWER</b>			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>ANAL HAEMORRHAGE</b>			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CONSTIPATION</b>			
subjects affected / exposed	0 / 157 (0.00%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>DIARRHOEA</b>			
subjects affected / exposed	1 / 157 (0.64%)	4 / 502 (0.80%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>GASTRITIS</b>			
subjects affected / exposed	0 / 157 (0.00%)	3 / 502 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>GASTROOESOPHAGEAL REFLUX DISEASE</b>			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>ILEUS</b>			

subjects affected / exposed	1 / 157 (0.64%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
INTESTINAL STRANGULATION			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
NAUSEA			
subjects affected / exposed	2 / 157 (1.27%)	9 / 502 (1.79%)	
occurrences causally related to treatment / all	0 / 3	2 / 11	
deaths causally related to treatment / all	0 / 1	0 / 1	
VOMITING			
subjects affected / exposed	0 / 157 (0.00%)	3 / 502 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
BILE DUCT STENOSIS			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BILIARY COLIC			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHOLECYSTITIS			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHOLECYSTITIS ACUTE			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHOLELITHIASIS			

subjects affected / exposed	0 / 157 (0.00%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
DRUG-INDUCED LIVER INJURY			
subjects affected / exposed	1 / 157 (0.64%)	6 / 502 (1.20%)	
occurrences causally related to treatment / all	1 / 1	7 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
HEPATIC CIRRHOSIS			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HEPATOTOXICITY			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
JAUNDICE			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
SKIN ULCER			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
ACUTE KIDNEY INJURY			
subjects affected / exposed	0 / 157 (0.00%)	6 / 502 (1.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 6	
deaths causally related to treatment / all	0 / 0	0 / 1	
HAEMATURIA			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
KIDNEY CONGESTION			

subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RENAL DISORDER			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RENAL FAILURE			
subjects affected / exposed	1 / 157 (0.64%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
RENAL IMPAIRMENT			
subjects affected / exposed	1 / 157 (0.64%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
URETERIC STENOSIS			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
URETEROLITHIASIS			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
URINARY INCONTINENCE			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
URINARY RETENTION			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
URINARY TRACT OBSTRUCTION			

subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
HYPERTHYROIDISM			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BACK PAIN			
subjects affected / exposed	0 / 157 (0.00%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
BONE LESION			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BONE PAIN			
subjects affected / exposed	2 / 157 (1.27%)	4 / 502 (0.80%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
FLANK PAIN			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LUMBAR SPINAL STENOSIS			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

MOBILITY DECREASED			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MUSCULOSKELETAL CHEST PAIN			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MUSCULOSKELETAL PAIN			
subjects affected / exposed	1 / 157 (0.64%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
OSTEITIS			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
OSTEOARTHRITIS			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
OSTEONECROSIS OF JAW			
subjects affected / exposed	0 / 157 (0.00%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
PAIN IN EXTREMITY			
subjects affected / exposed	0 / 157 (0.00%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
SPINAL PAIN			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			



ABDOMINAL ABSCESS			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ABSCCESS JAW			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
APPENDICITIS			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ATYPICAL PNEUMONIA			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BRONCHITIS			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHOLECYSTITIS INFECTIVE			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CYSTITIS			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CYSTITIS ESCHERICHIA			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEVICE RELATED INFECTION			

subjects affected / exposed	2 / 157 (1.27%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
<b>DIVERTICULITIS</b>			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>EMPHYSEMATOUS CHOLECYSTITIS</b>			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>ERYSIPELAS</b>			
subjects affected / exposed	0 / 157 (0.00%)	3 / 502 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>ESCHERICHIA INFECTION</b>			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>FEBRILE INFECTION</b>			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>GASTROENTERITIS</b>			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>GASTROINTESTINAL INFECTION</b>			
subjects affected / exposed	1 / 157 (0.64%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HELICOBACTER GASTRITIS</b>			

subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
INFECTIOUS PLEURAL EFFUSION			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
INFLUENZA			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MASTITIS			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PNEUMONIA			
subjects affected / exposed	2 / 157 (1.27%)	10 / 502 (1.99%)	
occurrences causally related to treatment / all	1 / 2	3 / 10	
deaths causally related to treatment / all	1 / 1	1 / 3	
PROTEUS INFECTION			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PYELONEPHRITIS			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RESPIRATORY SYNCYTIAL VIRUS INFECTION			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SEPSIS			

subjects affected / exposed	1 / 157 (0.64%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 2	
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
URINARY TRACT INFECTION			
subjects affected / exposed	0 / 157 (0.00%)	3 / 502 (0.60%)	
occurrences causally related to treatment / all	0 / 0	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
UROSEPSIS			
subjects affected / exposed	0 / 157 (0.00%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
DECREASED APPETITE			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEHYDRATION			
subjects affected / exposed	1 / 157 (0.64%)	2 / 502 (0.40%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERCALCAEMIA			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERKALAEMIA			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPONATRAEMIA			

subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HYPOPHAGIA</b>			
subjects affected / exposed	0 / 157 (0.00%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>TUMOUR LYSIS SYNDROME</b>			
subjects affected / exposed	1 / 157 (0.64%)	1 / 502 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	ribociclib + letrozole cohort A	ribociclib + letrozole cohort B	ribociclib + letrozole cohort B1
Total subjects affected by non-serious adverse events			
subjects affected / exposed	315 / 319 (98.75%)	181 / 183 (98.91%)	25 / 26 (96.15%)
<b>Vascular disorders</b>			
<b>HOT FLUSH</b>			
subjects affected / exposed	44 / 319 (13.79%)	30 / 183 (16.39%)	11 / 26 (42.31%)
occurrences (all)	49	35	13
<b>HYPERTENSION</b>			
subjects affected / exposed	36 / 319 (11.29%)	11 / 183 (6.01%)	4 / 26 (15.38%)
occurrences (all)	38	13	4
<b>General disorders and administration site conditions</b>			
<b>FATIGUE</b>			
subjects affected / exposed	123 / 319 (38.56%)	74 / 183 (40.44%)	15 / 26 (57.69%)
occurrences (all)	151	86	16
<b>OEDEMA PERIPHERAL</b>			
subjects affected / exposed	35 / 319 (10.97%)	22 / 183 (12.02%)	5 / 26 (19.23%)
occurrences (all)	37	31	7
<b>PYREXIA</b>			
subjects affected / exposed	23 / 319 (7.21%)	14 / 183 (7.65%)	4 / 26 (15.38%)
occurrences (all)	31	19	7
<b>Immune system disorders</b>			

SEASONAL ALLERGY subjects affected / exposed occurrences (all)	4 / 319 (1.25%) 4	6 / 183 (3.28%) 6	3 / 26 (11.54%) 3
Reproductive system and breast disorders VULVOVAGINAL DRYNESS subjects affected / exposed occurrences (all)	4 / 319 (1.25%) 5	3 / 183 (1.64%) 3	3 / 26 (11.54%) 3
Respiratory, thoracic and mediastinal disorders COUGH subjects affected / exposed occurrences (all)  DYSPNOEA subjects affected / exposed occurrences (all)  OROPHARYNGEAL PAIN subjects affected / exposed occurrences (all)	53 / 319 (16.61%) 66  49 / 319 (15.36%) 58  11 / 319 (3.45%) 12	22 / 183 (12.02%) 26  25 / 183 (13.66%) 26  7 / 183 (3.83%) 9	6 / 26 (23.08%) 7  4 / 26 (15.38%) 4  5 / 26 (19.23%) 7
Psychiatric disorders DEPRESSION subjects affected / exposed occurrences (all)  INSOMNIA subjects affected / exposed occurrences (all)  SLEEP DISORDER subjects affected / exposed occurrences (all)	7 / 319 (2.19%) 9  31 / 319 (9.72%) 34  13 / 319 (4.08%) 15	8 / 183 (4.37%) 8  26 / 183 (14.21%) 28  10 / 183 (5.46%) 10	2 / 26 (7.69%) 2  4 / 26 (15.38%) 5  4 / 26 (15.38%) 4
Investigations ALANINE AMINOTRANSFERASE INCREASED subjects affected / exposed occurrences (all)  ASPARTATE AMINOTRANSFERASE INCREASED subjects affected / exposed occurrences (all)  BLOOD BILIRUBIN INCREASED	75 / 319 (23.51%) 93  66 / 319 (20.69%) 82	36 / 183 (19.67%) 43  36 / 183 (19.67%) 44	6 / 26 (23.08%) 10  5 / 26 (19.23%) 8

subjects affected / exposed	16 / 319 (5.02%)	1 / 183 (0.55%)	0 / 26 (0.00%)
occurrences (all)	17	1	0
BLOOD CREATININE INCREASED			
subjects affected / exposed	27 / 319 (8.46%)	12 / 183 (6.56%)	2 / 26 (7.69%)
occurrences (all)	38	13	2
BLOOD LACTATE DEHYDROGENASE INCREASED			
subjects affected / exposed	17 / 319 (5.33%)	3 / 183 (1.64%)	1 / 26 (3.85%)
occurrences (all)	22	4	1
BLOOD THYROID STIMULATING HORMONE INCREASED			
subjects affected / exposed	0 / 319 (0.00%)	2 / 183 (1.09%)	2 / 26 (7.69%)
occurrences (all)	0	2	2
ELECTROCARDIOGRAM QT PROLONGED			
subjects affected / exposed	23 / 319 (7.21%)	14 / 183 (7.65%)	1 / 26 (3.85%)
occurrences (all)	29	19	1
GAMMA-GLUTAMYLTRANSFERASE INCREASED			
subjects affected / exposed	33 / 319 (10.34%)	18 / 183 (9.84%)	5 / 26 (19.23%)
occurrences (all)	38	20	5
NEUTROPHIL COUNT DECREASED			
subjects affected / exposed	40 / 319 (12.54%)	25 / 183 (13.66%)	2 / 26 (7.69%)
occurrences (all)	164	75	2
WEIGHT DECREASED			
subjects affected / exposed	16 / 319 (5.02%)	9 / 183 (4.92%)	0 / 26 (0.00%)
occurrences (all)	17	12	0
WEIGHT INCREASED			
subjects affected / exposed	7 / 319 (2.19%)	4 / 183 (2.19%)	2 / 26 (7.69%)
occurrences (all)	7	5	3
WHITE BLOOD CELL COUNT DECREASED			
subjects affected / exposed	27 / 319 (8.46%)	18 / 183 (9.84%)	2 / 26 (7.69%)
occurrences (all)	56	21	2
Injury, poisoning and procedural complications			
ARTHROPOD BITE			
subjects affected / exposed	3 / 319 (0.94%)	3 / 183 (1.64%)	2 / 26 (7.69%)
occurrences (all)	3	3	2

ARTHROPOD STING subjects affected / exposed occurrences (all)	0 / 319 (0.00%) 0	2 / 183 (1.09%) 2	2 / 26 (7.69%) 2
Nervous system disorders			
DIZZINESS			
subjects affected / exposed	26 / 319 (8.15%)	12 / 183 (6.56%)	4 / 26 (15.38%)
occurrences (all)	30	17	8
DYSGEUSIA			
subjects affected / exposed	20 / 319 (6.27%)	11 / 183 (6.01%)	4 / 26 (15.38%)
occurrences (all)	21	12	4
HEADACHE			
subjects affected / exposed	56 / 319 (17.55%)	36 / 183 (19.67%)	10 / 26 (38.46%)
occurrences (all)	90	55	20
HYPOAESTHESIA			
subjects affected / exposed	3 / 319 (0.94%)	5 / 183 (2.73%)	3 / 26 (11.54%)
occurrences (all)	3	5	3
POLYNEUROPATHY			
subjects affected / exposed	16 / 319 (5.02%)	5 / 183 (2.73%)	1 / 26 (3.85%)
occurrences (all)	17	5	1
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	46 / 319 (14.42%)	36 / 183 (19.67%)	7 / 26 (26.92%)
occurrences (all)	60	60	19
LEUKOPENIA			
subjects affected / exposed	76 / 319 (23.82%)	39 / 183 (21.31%)	8 / 26 (30.77%)
occurrences (all)	183	108	45
LYMPHOPENIA			
subjects affected / exposed	7 / 319 (2.19%)	2 / 183 (1.09%)	2 / 26 (7.69%)
occurrences (all)	14	13	13
NEUTROPENIA			
subjects affected / exposed	162 / 319 (50.78%)	88 / 183 (48.09%)	15 / 26 (57.69%)
occurrences (all)	558	326	95
THROMBOCYTOPENIA			
subjects affected / exposed	26 / 319 (8.15%)	18 / 183 (9.84%)	1 / 26 (3.85%)
occurrences (all)	46	23	2
Ear and labyrinth disorders			



VERTIGO			
subjects affected / exposed	33 / 319 (10.34%)	17 / 183 (9.29%)	4 / 26 (15.38%)
occurrences (all)	41	17	4
Eye disorders			
DRY EYE			
subjects affected / exposed	23 / 319 (7.21%)	10 / 183 (5.46%)	2 / 26 (7.69%)
occurrences (all)	24	11	2
LACRIMATION INCREASED			
subjects affected / exposed	34 / 319 (10.66%)	11 / 183 (6.01%)	2 / 26 (7.69%)
occurrences (all)	38	11	2
Gastrointestinal disorders			
ABDOMINAL PAIN			
subjects affected / exposed	15 / 319 (4.70%)	14 / 183 (7.65%)	5 / 26 (19.23%)
occurrences (all)	21	17	7
ABDOMINAL PAIN UPPER			
subjects affected / exposed	33 / 319 (10.34%)	13 / 183 (7.10%)	3 / 26 (11.54%)
occurrences (all)	42	20	7
CONSTIPATION			
subjects affected / exposed	62 / 319 (19.44%)	32 / 183 (17.49%)	4 / 26 (15.38%)
occurrences (all)	71	43	4
DIARRHOEA			
subjects affected / exposed	85 / 319 (26.65%)	40 / 183 (21.86%)	8 / 26 (30.77%)
occurrences (all)	133	57	16
DRY MOUTH			
subjects affected / exposed	28 / 319 (8.78%)	10 / 183 (5.46%)	1 / 26 (3.85%)
occurrences (all)	30	10	1
DYSPEPSIA			
subjects affected / exposed	25 / 319 (7.84%)	14 / 183 (7.65%)	2 / 26 (7.69%)
occurrences (all)	28	14	2
NAUSEA			
subjects affected / exposed	130 / 319 (40.75%)	77 / 183 (42.08%)	9 / 26 (34.62%)
occurrences (all)	202	108	11
STOMATITIS			
subjects affected / exposed	33 / 319 (10.34%)	27 / 183 (14.75%)	4 / 26 (15.38%)
occurrences (all)	40	30	4
TOOTHACHE			

subjects affected / exposed occurrences (all)	9 / 319 (2.82%) 10	4 / 183 (2.19%) 4	2 / 26 (7.69%) 2
VOMITING subjects affected / exposed occurrences (all)	66 / 319 (20.69%) 93	31 / 183 (16.94%) 63	5 / 26 (19.23%) 10
Skin and subcutaneous tissue disorders			
ALOPECIA subjects affected / exposed occurrences (all)	119 / 319 (37.30%) 127	57 / 183 (31.15%) 63	5 / 26 (19.23%) 7
DRY SKIN subjects affected / exposed occurrences (all)	24 / 319 (7.52%) 27	15 / 183 (8.20%) 16	3 / 26 (11.54%) 3
ERYTHEMA subjects affected / exposed occurrences (all)	9 / 319 (2.82%) 9	10 / 183 (5.46%) 10	1 / 26 (3.85%) 1
PRURITUS subjects affected / exposed occurrences (all)	45 / 319 (14.11%) 53	18 / 183 (9.84%) 19	3 / 26 (11.54%) 4
RASH subjects affected / exposed occurrences (all)	47 / 319 (14.73%) 60	19 / 183 (10.38%) 25	2 / 26 (7.69%) 3
Musculoskeletal and connective tissue disorders			
ARTHRALGIA subjects affected / exposed occurrences (all)	57 / 319 (17.87%) 76	39 / 183 (21.31%) 47	9 / 26 (34.62%) 12
BACK PAIN subjects affected / exposed occurrences (all)	37 / 319 (11.60%) 42	24 / 183 (13.11%) 29	4 / 26 (15.38%) 6
BONE PAIN subjects affected / exposed occurrences (all)	35 / 319 (10.97%) 42	15 / 183 (8.20%) 18	6 / 26 (23.08%) 9
MUSCULOSKELETAL CHEST PAIN subjects affected / exposed occurrences (all)	12 / 319 (3.76%) 13	6 / 183 (3.28%) 7	2 / 26 (7.69%) 2
MUSCULOSKELETAL PAIN			

subjects affected / exposed occurrences (all)	21 / 319 (6.58%) 27	14 / 183 (7.65%) 15	2 / 26 (7.69%) 3
MYALGIA subjects affected / exposed occurrences (all)	18 / 319 (5.64%) 18	6 / 183 (3.28%) 7	0 / 26 (0.00%) 0
PAIN IN EXTREMITY subjects affected / exposed occurrences (all)	52 / 319 (16.30%) 68	23 / 183 (12.57%) 35	3 / 26 (11.54%) 5
Infections and infestations BRONCHITIS subjects affected / exposed occurrences (all)	19 / 319 (5.96%) 25	5 / 183 (2.73%) 6	1 / 26 (3.85%) 1
CYSTITIS subjects affected / exposed occurrences (all)	21 / 319 (6.58%) 25	9 / 183 (4.92%) 10	3 / 26 (11.54%) 3
GASTROINTESTINAL INFECTION subjects affected / exposed occurrences (all)	2 / 319 (0.63%) 2	3 / 183 (1.64%) 3	2 / 26 (7.69%) 2
NASOPHARYNGITIS subjects affected / exposed occurrences (all)	94 / 319 (29.47%) 131	49 / 183 (26.78%) 74	10 / 26 (38.46%) 18
URINARY TRACT INFECTION subjects affected / exposed occurrences (all)	31 / 319 (9.72%) 45	17 / 183 (9.29%) 23	1 / 26 (3.85%) 2
Metabolism and nutrition disorders DECREASED APPETITE subjects affected / exposed occurrences (all)	44 / 319 (13.79%) 45	19 / 183 (10.38%) 20	1 / 26 (3.85%) 1
HYPERKALAEMIA subjects affected / exposed occurrences (all)	6 / 319 (1.88%) 18	4 / 183 (2.19%) 6	2 / 26 (7.69%) 4
HYPOCALCAEMIA subjects affected / exposed occurrences (all)	8 / 319 (2.51%) 10	5 / 183 (2.73%) 5	2 / 26 (7.69%) 2

<b>Non-serious adverse events</b>	ribociclib + letrozole cohort B2	Total	
-----------------------------------	-------------------------------------	-------	--

Total subjects affected by non-serious adverse events			
subjects affected / exposed	156 / 157 (99.36%)	496 / 502 (98.80%)	
Vascular disorders			
HOT FLUSH			
subjects affected / exposed	19 / 157 (12.10%)	74 / 502 (14.74%)	
occurrences (all)	22	84	
HYPERTENSION			
subjects affected / exposed	7 / 157 (4.46%)	47 / 502 (9.36%)	
occurrences (all)	9	51	
General disorders and administration site conditions			
FATIGUE			
subjects affected / exposed	59 / 157 (37.58%)	197 / 502 (39.24%)	
occurrences (all)	70	237	
OEDEMA PERIPHERAL			
subjects affected / exposed	17 / 157 (10.83%)	57 / 502 (11.35%)	
occurrences (all)	24	68	
PYREXIA			
subjects affected / exposed	10 / 157 (6.37%)	37 / 502 (7.37%)	
occurrences (all)	12	50	
Immune system disorders			
SEASONAL ALLERGY			
subjects affected / exposed	3 / 157 (1.91%)	10 / 502 (1.99%)	
occurrences (all)	3	10	
Reproductive system and breast disorders			
VULVOVAGINAL DRYNESS			
subjects affected / exposed	0 / 157 (0.00%)	7 / 502 (1.39%)	
occurrences (all)	0	8	
Respiratory, thoracic and mediastinal disorders			
COUGH			
subjects affected / exposed	16 / 157 (10.19%)	75 / 502 (14.94%)	
occurrences (all)	19	92	
DYSPNOEA			
subjects affected / exposed	21 / 157 (13.38%)	74 / 502 (14.74%)	
occurrences (all)	22	84	
OROPHARYNGEAL PAIN			

subjects affected / exposed occurrences (all)	2 / 157 (1.27%) 2	18 / 502 (3.59%) 21	
Psychiatric disorders DEPRESSION subjects affected / exposed occurrences (all)	6 / 157 (3.82%) 6	15 / 502 (2.99%) 17	
INSOMNIA subjects affected / exposed occurrences (all)	22 / 157 (14.01%) 23	57 / 502 (11.35%) 62	
SLEEP DISORDER subjects affected / exposed occurrences (all)	6 / 157 (3.82%) 6	23 / 502 (4.58%) 25	
Investigations ALANINE AMINOTRANSFERASE INCREASED subjects affected / exposed occurrences (all)	30 / 157 (19.11%) 33	111 / 502 (22.11%) 136	
ASPARTATE AMINOTRANSFERASE INCREASED subjects affected / exposed occurrences (all)	31 / 157 (19.75%) 36	102 / 502 (20.32%) 126	
BLOOD BILIRUBIN INCREASED subjects affected / exposed occurrences (all)	1 / 157 (0.64%) 1	17 / 502 (3.39%) 18	
BLOOD CREATININE INCREASED subjects affected / exposed occurrences (all)	10 / 157 (6.37%) 11	39 / 502 (7.77%) 51	
BLOOD LACTATE DEHYDROGENASE INCREASED subjects affected / exposed occurrences (all)	2 / 157 (1.27%) 3	20 / 502 (3.98%) 26	
BLOOD THYROID STIMULATING HORMONE INCREASED subjects affected / exposed occurrences (all)	0 / 157 (0.00%) 0	2 / 502 (0.40%) 2	
ELECTROCARDIOGRAM QT PROLONGED subjects affected / exposed occurrences (all)	13 / 157 (8.28%) 18	37 / 502 (7.37%) 48	

<p>GAMMA-GLUTAMYLTRANSFERASE INCREASED</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>NEUTROPHIL COUNT DECREASED</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>WEIGHT DECREASED</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>WEIGHT INCREASED</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>WHITE BLOOD CELL COUNT DECREASED</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	13 / 157 (8.28%)	51 / 502 (10.16%)	
	15	58	
	23 / 157 (14.65%)	65 / 502 (12.95%)	
	73	239	
	9 / 157 (5.73%)	25 / 502 (4.98%)	
	12	29	
	2 / 157 (1.27%)	11 / 502 (2.19%)	
	2	12	
	16 / 157 (10.19%)	45 / 502 (8.96%)	
	19	77	
<p>Injury, poisoning and procedural complications</p> <p>ARTHROPOD BITE</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>ARTHROPOD STING</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	1 / 157 (0.64%)	6 / 502 (1.20%)	
	1	6	
	0 / 157 (0.00%)	2 / 502 (0.40%)	
	0	2	
<p>Nervous system disorders</p> <p>DIZZINESS</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>DYSGEUSIA</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>HEADACHE</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>HYPOAESTHESIA</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	8 / 157 (5.10%)	38 / 502 (7.57%)	
	9	47	
	7 / 157 (4.46%)	31 / 502 (6.18%)	
	8	33	
	26 / 157 (16.56%)	92 / 502 (18.33%)	
	35	145	
	2 / 157 (1.27%)	8 / 502 (1.59%)	
	2	8	

POLYNEUROPATHY subjects affected / exposed occurrences (all)	4 / 157 (2.55%) 4	21 / 502 (4.18%) 22	
Blood and lymphatic system disorders ANAEMIA subjects affected / exposed occurrences (all)	29 / 157 (18.47%) 41	82 / 502 (16.33%) 120	
LEUKOPENIA subjects affected / exposed occurrences (all)	31 / 157 (19.75%) 63	115 / 502 (22.91%) 291	
LYMPHOPENIA subjects affected / exposed occurrences (all)	0 / 157 (0.00%) 0	9 / 502 (1.79%) 27	
NEUTROPENIA subjects affected / exposed occurrences (all)	73 / 157 (46.50%) 231	250 / 502 (49.80%) 884	
THROMBOCYTOPENIA subjects affected / exposed occurrences (all)	17 / 157 (10.83%) 21	44 / 502 (8.76%) 69	
Ear and labyrinth disorders VERTIGO subjects affected / exposed occurrences (all)	13 / 157 (8.28%) 13	50 / 502 (9.96%) 58	
Eye disorders DRY EYE subjects affected / exposed occurrences (all)	8 / 157 (5.10%) 9	33 / 502 (6.57%) 35	
LACRIMATION INCREASED subjects affected / exposed occurrences (all)	9 / 157 (5.73%) 9	45 / 502 (8.96%) 49	
Gastrointestinal disorders ABDOMINAL PAIN subjects affected / exposed occurrences (all)	9 / 157 (5.73%) 10	29 / 502 (5.78%) 38	
ABDOMINAL PAIN UPPER subjects affected / exposed occurrences (all)	10 / 157 (6.37%) 13	46 / 502 (9.16%) 62	

CONSTIPATION			
subjects affected / exposed	28 / 157 (17.83%)	94 / 502 (18.73%)	
occurrences (all)	39	114	
DIARRHOEA			
subjects affected / exposed	32 / 157 (20.38%)	125 / 502 (24.90%)	
occurrences (all)	41	190	
DRY MOUTH			
subjects affected / exposed	9 / 157 (5.73%)	38 / 502 (7.57%)	
occurrences (all)	9	40	
DYSPEPSIA			
subjects affected / exposed	12 / 157 (7.64%)	39 / 502 (7.77%)	
occurrences (all)	12	42	
NAUSEA			
subjects affected / exposed	68 / 157 (43.31%)	207 / 502 (41.24%)	
occurrences (all)	97	310	
STOMATITIS			
subjects affected / exposed	23 / 157 (14.65%)	60 / 502 (11.95%)	
occurrences (all)	26	70	
TOOTHACHE			
subjects affected / exposed	2 / 157 (1.27%)	13 / 502 (2.59%)	
occurrences (all)	2	14	
VOMITING			
subjects affected / exposed	26 / 157 (16.56%)	97 / 502 (19.32%)	
occurrences (all)	53	156	
Skin and subcutaneous tissue disorders			
ALOPECIA			
subjects affected / exposed	52 / 157 (33.12%)	176 / 502 (35.06%)	
occurrences (all)	56	190	
DRY SKIN			
subjects affected / exposed	12 / 157 (7.64%)	39 / 502 (7.77%)	
occurrences (all)	13	43	
ERYTHEMA			
subjects affected / exposed	9 / 157 (5.73%)	19 / 502 (3.78%)	
occurrences (all)	9	19	
PRURITUS			



subjects affected / exposed	15 / 157 (9.55%)	63 / 502 (12.55%)	
occurrences (all)	15	72	
RASH			
subjects affected / exposed	17 / 157 (10.83%)	66 / 502 (13.15%)	
occurrences (all)	22	85	
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
subjects affected / exposed	30 / 157 (19.11%)	96 / 502 (19.12%)	
occurrences (all)	35	123	
BACK PAIN			
subjects affected / exposed	20 / 157 (12.74%)	61 / 502 (12.15%)	
occurrences (all)	23	71	
BONE PAIN			
subjects affected / exposed	9 / 157 (5.73%)	50 / 502 (9.96%)	
occurrences (all)	9	60	
MUSCULOSKELETAL CHEST PAIN			
subjects affected / exposed	4 / 157 (2.55%)	18 / 502 (3.59%)	
occurrences (all)	5	20	
MUSCULOSKELETAL PAIN			
subjects affected / exposed	12 / 157 (7.64%)	35 / 502 (6.97%)	
occurrences (all)	12	42	
MYALGIA			
subjects affected / exposed	6 / 157 (3.82%)	24 / 502 (4.78%)	
occurrences (all)	7	25	
PAIN IN EXTREMITY			
subjects affected / exposed	20 / 157 (12.74%)	75 / 502 (14.94%)	
occurrences (all)	30	103	
Infections and infestations			
BRONCHITIS			
subjects affected / exposed	4 / 157 (2.55%)	24 / 502 (4.78%)	
occurrences (all)	5	31	
CYSTITIS			
subjects affected / exposed	6 / 157 (3.82%)	30 / 502 (5.98%)	
occurrences (all)	7	35	
GASTROINTESTINAL INFECTION			

subjects affected / exposed occurrences (all)	1 / 157 (0.64%) 1	5 / 502 (1.00%) 5	
NASOPHARYNGITIS subjects affected / exposed occurrences (all)	39 / 157 (24.84%) 56	143 / 502 (28.49%) 205	
URINARY TRACT INFECTION subjects affected / exposed occurrences (all)	16 / 157 (10.19%) 21	48 / 502 (9.56%) 68	
Metabolism and nutrition disorders DECREASED APPETITE subjects affected / exposed occurrences (all)	18 / 157 (11.46%) 19	63 / 502 (12.55%) 65	
HYPERKALAEMIA subjects affected / exposed occurrences (all)	2 / 157 (1.27%) 2	10 / 502 (1.99%) 24	
HYPOCALCAEMIA subjects affected / exposed occurrences (all)	3 / 157 (1.91%) 3	13 / 502 (2.59%) 15	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
30 September 2016	The purpose of this amendment was to include feedback received from BfArM and ECs during the assessment of the initial application.
03 May 2017	This amendment was intended to update the existing information about ribociclib, to clarify specific aspects of the original protocol and to introduce the option for treatment beyond radiologic progression at the investigators discretion.
14 August 2017	This amendment was intended to correct mistakes in the protocol
05 May 2019	This amendment was intended to update the existing information about ribociclib, to clarify specific aspects of the original protocol and to introduce the option for treatment beyond radiologic progression at the investigators discretion.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported